Crossmark

Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial

Crossref DOI link: https://doi.org/10.1038/s41392-024-01974-2

Published Online: 2024-09-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Yaxiong https://orcid.org/0000-0002-3632-0300
Huang, Yan

Yang, Yunpeng

Zhao, Yuanyuan

Zhou, Ting

Chen, Gang

Zhao, Shen https://orcid.org/0000-0003-1289-5609
Zhou, Huaqiang https://orcid.org/0000-0003-3538-4481
Ma, Yuxiang

Hong, Shaodong

Zhao, Hongyun https://orcid.org/0000-0002-1251-3888
Zhang, Li

Fang, Wenfeng
License Information

Text and Data Mining valid from 2024-09-27

Version of Record valid from 2024-09-27
More Information

Article History

Received: 4 April 2024

Revised: 1 September 2024

Accepted: 13 September 2024

First Online: 27 September 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below